Breaking News, Trials & Filings

Regeneron Pharmaceuticals Secures EC Approval for Ordspono

The EC approval was based on data from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials.

Author Image

By: Charlie Sternberg

Associate Editor

Regeneron Pharmaceuticals has secured European Commission (EC) approval for Ordspono (odronextamab) to treat relapsed or refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Ordspono, a bispecific antibody, targets lymphoma cells and links them to killer T cells. This marks the first global regulatory approval for Ordspono in these indications.   “The EC approval of Ordspono is a meaningful advancement for EU patients and their physicians as a new option to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters